Posted on April 1, 2021 by Sitemaster
According to a recent article in Modern Pathology, a team of researchers at Yale University and at Memorial Sloan-Kettering Cancer Center (MSKCC) have been able to show that an artificial intelligence (AI) system designed and validated at MSKCC could be used to diagnose prostate cancer as either “suspicious” or “not suspicious” based on data from nearly 2,000 slides of prostate tissue acquired at Yale Medicine. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: AI, artificial, biopsy, intelligence, pathology, slide | 4 Comments »
Posted on March 23, 2021 by Sitemaster
According to a media release, issued earlier today by Novartis, the company has provided preliminary data about the results of the international, multi-center, Phase III, randomized, VISION trial, which has been evaluating the efficacy and safety of lutetium-177 PSMA-617, a targeted radioligand therapy, in treatment of men with progressive, PSMA-positive, metastatic, castration-resistant prostate cancer (mCRPC) … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, lutetium-177, mCRPC, metastatic, PSMA, PSMA-617 | 3 Comments »
Posted on March 22, 2021 by Sitemaster
As some of our readers will already be aware, Prostate Cancer International has been working in concert with Dr. M. Mihaj Siddiqui at the University of Maryland School of Medicine and the PATIENTS program at the University of Maryland School of Pharmacy to put together a grant request for funding for a program to identify evidence gaps to guide future research on the use of active surveillance to monitor low-risk prostate cancers. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, initiative, research, surveillance | 3 Comments »
Posted on March 22, 2021 by Sitemaster
As Howard Wolinsky has been learning over the past few years, not all prostate cancer support groups are “equal” — in the sense that individual support group leaders may be seriously biased by their own personal experiences (which may have occurred many years ago). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: bias, group, support | Leave a comment »
Posted on March 10, 2021 by Sitemaster
So (in our opinion) the time has come — for a whole bunch of reasons — for actual and potential prostate cancer patients to start asking their urologists about whether they are able to carry out transperineal as opposed to transrectal biopsies. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer | Tagged: benefit, biopsy, risk, transperineal, transrectal | 12 Comments »
Posted on March 1, 2021 by Sitemaster
In February, a group of researchers initiated a major new survey of patient knowledge about active surveillance as an initial management option for men with lower risk forms of prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, knowledge, patient, surveillance, survey | Leave a comment »
Posted on February 25, 2021 by Sitemaster
Xofigo (radium Ra 223 dichloride) is a systemic radiopharmaceutical. Radium is chemically similar to calcium and is taken up by bones in places where bone is actively growing, as in prostate cancer bone metastases. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: combination, radium-223, therapy, Xofigo | Leave a comment »
Posted on February 15, 2021 by Sitemaster
As we have mentioned previously, data on the use of a variety of methods of urine testing in assessment of risk for clinically significant prostate cancer (and therefore the need for a follow-up biopsy) continues to evolve. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: MyProstateScore, risk, test, urine | Leave a comment »
Posted on February 15, 2021 by Sitemaster
We saw recently (see this link) that of chemotherapeutic and hormonal medicines for treatment of metastatic castration-resistant prostate cancer (mCRPC), Jevtana (cabazitaxel) is the preferred third-line treatment after Taxotere (docetaxel) and Zytiga (abiraterone acetate) or Xtandi (enzalutamide). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: cabazitaxel, Jevtana, Lu-177-PSMA-617, mCRPC | 3 Comments »
Posted on February 9, 2021 by Sitemaster
The abstract of a presentation to be given by Egan et al. — from the National Institutes of Health (NIH) at Bethesda, MD — at the upcoming, virtual Genitourinary Cancers Symposium has indicated that active surveillance (AS) seems to be a very reasonable option for first-line management for compliant patients initially diagnosed with Grade Group 2 prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: 2, active, grade group, progression, surveillance | 9 Comments »
Posted on February 8, 2021 by Sitemaster
The “best” way to identify clinically significant, localized prostate cancer continues to evolve. But there is still no consensus about what that “best” way might be to do this, let alone any consensus about the detection of “clinically insignificant”, localized prostate cancer. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, Diagnosis, MRi-guided, risk, systematic | Leave a comment »
Posted on February 4, 2021 by Sitemaster
Early in 2020, in the initial stages of the COVID-19 pandemic, there was a suggestion (based on data from a small Italian study) that men who were using androgen deprivation therapy (ADT) to manage their prostate cancer might be at lower than average risk for becoming infected with this virus. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation, COVID-19, risk | 3 Comments »
Posted on February 1, 2021 by Sitemaster
As we await the results of the VISION trial of Lu-177-PSMA-617, research continues into improving radiopharmaceuticals. … READ MORE …
Filed under: Drugs in development | Tagged: Ac-225, actinium-225, PSMA, radiopharmaceuticals, safety, side effects, targeted, xerostomia | 3 Comments »
Posted on January 29, 2021 by Sitemaster
Two technologies have come together to allow for a new kind of radiation treatment known as simultaneous integrated boost (SIB), or, more informally, “dose painting.” … READ MORE …
Filed under: Diagnosis, Management, Treatment | Tagged: boost, dose painting, integrated, radiation, SIB, simultaneous | 5 Comments »
Posted on January 26, 2021 by Sitemaster
As we have seen, stereotactic body radiation therapy (SBRT) is a preferred therapy for low- and intermediate-risk patients (see this link). It is effective, safe, convenient, and relatively inexpensive. However, its use for high-risk patients remains controversial. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: "high risk", intermediate risk, outcomes, radiation | 5 Comments »
